Healthcare Sales & Marketing Network News: lung disease

Searching News Database: lung disease

HSMN NewsFeed - 24 Feb 2026
Brainomix Extends Series C Financing to $25.4M (£18.8M) to Support U.S. Expansion
Devices Radiology Venture Capital

HSMN NewsFeed - 19 Feb 2026
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Feb 2026
Synchrony Medical Secures $5M Funding to Fuel Commercial Expansion of its At-Home Airway Clearance Device for Chronic Respiratory Disease
Devices Venture Capital

HSMN NewsFeed - 22 Dec 2025
U.S. FDA Approves JASCAYD(R) (nerandomilast) Tablets for the Treatment of Progressive Pulmonary Fibrosis in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2025
CMS Finalizes OPPS Payment for Eko Health's SENSORA(R) Platform, Expanding Reimbursement for AI-Enabled Cardiac Disease Detection in Hospital-Associated Outpatient Care
Devices Cardiology Reimbursement

HSMN NewsFeed - 11 Nov 2025
New Study Shows Aliya(R) Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patients and May Induce an Immune Response
Devices Oncology

HSMN NewsFeed - 1 May 2025
Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Dec 2023
Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Jul 2023
Viatris Announces Launch of Breyna(TM) (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort(R) for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 20 Jul 2022
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
Biopharmaceuticals FDA

HSMN NewsFeed - 23 May 2022
Insmed Names Drayton Wise Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2022
Israeli startup Sanolla receives FDA clearance for the world's first AI-ready infrasound stethoscope
Devices FDA

HSMN NewsFeed - 3 Feb 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
Devices Venture Capital

HSMN NewsFeed - 18 Nov 2021
Strados Labs Granted CE Mark for its RESP(TM) Smart Sensor Platform
Devices Monitoring Regulatory

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jun 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 27 Apr 2021
Medtronic Receives FDA Breakthrough Designation for the Emprint(TM) Ablation Catheter Kit
Devices FDA

HSMN NewsFeed - 22 Apr 2021
Getinge receives US FDA 510(k) clearance for three products, expanding the Servo ventilator platform
Devices FDA

HSMN NewsFeed - 15 Apr 2021
Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
Devices Venture Capital

HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Feb 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
Regenerative Medicine Acquisitions

HSMN NewsFeed - 18 Jan 2021
New Treatment for Severe Emphysema Now Covered Under Highmark Blue Cross Blue Shield
Devices Reimbursement

HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 15 Jun 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2020
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Biopharmaceuticals FDA

HSMN NewsFeed - 13 May 2020
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2020
VIDA Completes Second Close Of Round C Financing
Devices Venture Capital

HSMN NewsFeed - 8 Apr 2020
Third Pole Therapeutics Announces Global Commercialization Agreement with Chiesi Group for Its Tankless, Portable Inhaled Nitric Oxide (iNO) Delivery System
Biopharmaceuticals Licensing

HSMN NewsFeed - 2 Apr 2020
Insmed Appoints Carol A. Schafer to its Board of Directors
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 30 Jan 2020
Insmed Appoints Sara Bonstein as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Jan 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
Biopharmaceuticals Oncology Drug Delivery Licensing

HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Oct 2019
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Oct 2019
VIDA Expands Board, Announcing Erkan Akyuz As Independent Director
Devices Radiology Oncology Personnel

HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Aug 2019
Hillrom Announces Acquisition Of Breathe Technologies
Devices Mergers & Acquisitions

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 May 2019
Pulmatrix Announces Leadership Change
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 10 Apr 2019
Getinge Receives 510(k) Clearance From US FDA for Software Upgrade in Servo-u(R) and Servo-n(R) Ventilator Platform
Devices FDA

HSMN NewsFeed - 3 Apr 2019
CSA Medical, Inc. Receives FDA Breakthrough Device Designation and IDE Approval for its RejuvenAir(R) System for COPD Patients with Chronic Bronchitis
Devices FDA

HSMN NewsFeed - 26 Mar 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Feb 2019
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD
Devices Venture Capital Personnel

HSMN NewsFeed - 5 Dec 2018
Olympus Spiration(R) Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema
Devices FDA

HSMN NewsFeed - 27 Nov 2018
Mesa Biotech Receives FDA 510(k) Clearance and CLIA Waiver for Its Accula(TM) RSV Molecular Point of Care Test
Diagnostics FDA

HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 11 Oct 2018
FDA Approves Stiolto(R) Respimat(R) Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jun 2018
Henry Schein Medical Launches Its New EasyOne Air Spirometer
Devices Product Launch

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2018
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 3 Apr 2018
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Jan 2018
Olympus PeriView FLEX TBNA Needle Brings New Capabilities to Early Diagnosis of Lung Disease
Devices Product Launch

HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2017
Spero Therapeutics Appoints Joel Sendek as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2017
Savara Announces Expedited U.S. Molgradex Development Strategy
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Mar 2017
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Oct 2016
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Biopharmaceuticals

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Oct 2016
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Sep 2016
Insmed Appoints Roger Adsett as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Sep 2016
KVK Tech Announces FDA-Approval of Lomaira(TM) (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up To Three Times Daily for Weight Reduction
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Sep 2016
New Data: STIOLTO(R) RESPIMAT(R) (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
Biopharmaceuticals Devices Drug Delivery

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Aug 2016
Alere Receives FDA Clearance for Alere(TM) i RSV Rapid Molecular Test
Diagnostics FDA

HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jun 2016
Savara Pharmaceuticals Acquires Serendex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Apr 2016
VolitionRx Announces CE Marks for Two NuQ(R) Blood Assays for Detection of Colorectal Cancer
Diagnostics Oncology Regulatory

HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2016
Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma(R) Gene Expression Classifier in Thyroid Cancer Diagnosis
Diagnostics Oncology

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2016
Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma(R) Gene Expression Classifier
Diagnostics Oncology

HSMN NewsFeed - 15 Dec 2015
Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Oct 2015
Medtronic Launches superDimension(TM) Lung Navigation Software With Suggested Fiducial Marker Placement
Devices Interventional Product Launch

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2015
Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer
Diagnostics Oncology Personnel

HSMN NewsFeed - 20 Jul 2015
aTyr Pharma Announces Transitions In Clinical Development & Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Oct 2014
Covidien Launches Next-Generation SuperDimension(TM) Lung Navigation Software to Simplify Planning, Enhance Visualization During a Procedure
Devices Oncology Product Launch

HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex(R) for the Treatment of Cystic Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Sep 2014
Airway Therapeutics Raises $4.6 Million in Series A Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Aug 2014
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
Biopharmaceuticals Endocrinology Drug Delivery Licensing

HSMN NewsFeed - 5 Aug 2014
Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2014
FDA Approves Boehringer Ingelheim's Striverdi(R) Respimat(R) (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jun 2014
GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD
Biopharmaceuticals

HSMN NewsFeed - 22 May 2014
Santhera Reports Positive Outcome for Catena(R)/Raxone(R) in Phase III DMD Trial Supported by Additional Respiratory Function Data
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2014
Holaira Closes $42 Million Venture Financing Round
Devices Venture Capital Personnel

HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2014
InterMune(R) Announces Support for First Ever European Patient Charter on Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals

HSMN NewsFeed - 25 Feb 2014
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals

HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Sep 2013
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 May 2013
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Apr 2013
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
Diagnostics Personnel

HSMN NewsFeed - 12 Mar 2013
Allegro Diagnostics Announces BronchoGen(TM) Genomic Test for Improved Diagnosis of Lung Cancer Successfully Achieves Clinical Validation
Diagnostics Oncology

HSMN NewsFeed - 26 Feb 2013
Holaira Bolsters Executive Team
Devices Personnel

HSMN NewsFeed - 26 Feb 2013
Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer
Regenerative Medicine Personnel

HSMN NewsFeed - 17 Jan 2013
Sanovas Files for FDA Clearance of Vas Zeppelin(TM) Smart Catheter(TM)
Devices Interventional FDA

HSMN NewsFeed - 10 Dec 2012
ApniCure Appoints David P. White, M.D., as Chief Scientific Officer
Devices Personnel

HSMN NewsFeed - 8 Nov 2012
Genoa Pharmaceuticals announces $1.2M Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Nov 2012
Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 26 Oct 2012
NICE Approves Pharmaxis' Bronchitol(R) As An Important New Treatment Option For Cystic Fibrosis Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Sep 2012
Seebri(R) Inhalation Capsules Receive MHLW Approval as Once-daily Maintenance Treatment for COPD in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Sep 2012
Innovative Pulmonary Solutions Names Dennis Wahr, M.D., as President and CEO and Announces Series B Financing Milestone
Devices Venture Capital Personnel

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Sep 2012
Insmed Appoints Will Lewis as President and Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jun 2012
Allegro Diagnostics Appoints Clinical and Scientific Advisory Board Comprised of Experts in Pulmonology, Lung Cancer and Molecular Diagnostics
Diagnostics Oncology Personnel

HSMN NewsFeed - 21 May 2012
PneumRx, Inc. Acquires Key Assets From Broncus
Devices Acquisitions

HSMN NewsFeed - 18 May 2012
ApniCure Receives FDA 510(k) Clearance to Market Winx(TM) Sleep Therapy System for Treatment of Obstructive Sleep Apnea
Devices FDA

HSMN NewsFeed - 16 May 2012
Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2012
Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE(R) in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2012
Richard T. Kloos, M.D., Joins Veracyte as Senior Medical Director
Diagnostics Personnel

HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Mar 2012
Covidien Announces Definitive Agreement to Acquire superDimension, Ltd.
Devices Interventional Mergers & Acquisitions

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 20 Jan 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Diagnostics Endocrinology Oncology Personalized Medicine

HSMN NewsFeed - 20 Jan 2012
Insmed Incorporated Provides Corporate Update
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2011
InterMune Announces Launch of Esbriet(R) (pirfenidone) in Germany
Biopharmaceuticals

HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Mar 2011
Breathe Technologies Receives FDA Clearance for Home Use of Portable Ventilator
Devices Personnel FDA

HSMN NewsFeed - 3 Mar 2011
InterMune Receives European Union Approval for Esbriet(R) (pirfenidone)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2011
Forest Announces FDA Approval of Daliresp(TM) (Roflumilast) as a Treatment to Reduce the Risk of COPD Exacerbations in Patients with Severe COPD Associated with Chronic Bronchitis and a History of Exacerbations
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Feb 2011
Study Shows Improved Detection of Lung Cancer Nodules with Riverain Medical’s CAD Chest X-ray Technology
Devices Radiology Oncology

HSMN NewsFeed - 31 Jan 2011
CyberKnife Radiosurgery to be Highlighted by Leading Thoracic Surgeons at 2011 STS Annual Meeting
Devices Oncology

HSMN NewsFeed - 4 Jan 2011
PneumRx, Inc. Raises $33 Million in Capital
Devices Venture Capital

HSMN NewsFeed - 3 Jan 2011
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2010
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Nov 2010
Uptake Medical Names J.C. MacRae as Chief Financial Officer
Devices Personnel

HSMN NewsFeed - 15 Nov 2010
Breathe Technologies Appoints New CEO
Devices Personnel

HSMN NewsFeed - 1 Nov 2010
Steven Kesten, M.D., Leader in Pulmonary Medicine, Joins Uptake Medical as Vice President and Chief Medical Officer
Devices Personnel

HSMN NewsFeed - 20 Sep 2010
Aeris Therapeutics Announces CE Mark Approval for the AeriSeal(R) Emphysematous Lung Sealant System
Devices Regulatory

HSMN NewsFeed - 24 Aug 2010
Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for GLASSIA
Biopharmaceuticals Distribution

HSMN NewsFeed - 13 Aug 2010
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jul 2010
Uptake Medical Completes Series B Financing Round for $17.5 Million
Devices Venture Capital

HSMN NewsFeed - 25 Jun 2010
Olympus to Acquire Spiration, Inc., a U.S. Pulmonary Device Company, as a Consolidated Subsidiary
Devices Mergers & Acquisitions

HSMN NewsFeed - 24 Jun 2010
FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2010
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 May 2010
MitraClip Safely Relieves Symptoms in Patients With No Surgical Options
Devices Interventional Cardiology

HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Apr 2010
CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Mar 2010
Tomophase Corporation Names Ralph S. Johnston President and Chief Operating Officer
Devices Personnel

HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Mar 2010
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Nov 2009
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 19 Oct 2009
Covidien Announces Global Launch of Mallinckrodt TaperGuard Line of Endotracheal Tubes
Devices

HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2009
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals

HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Biopharmaceuticals

HSMN NewsFeed - 19 May 2009
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Biopharmaceuticals

HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jan 2009
MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2008
Broncus Technologies Secures $38 Million in Funding Round Led by Ares Life Sciences
Devices Venture Capital

HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 8 Oct 2008
Spiration, Inc. Announces European Launch of Minimally Invasive Pulmonary Device
Devices

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 30 Sep 2008
APT Pharmaceuticals Secures $32 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals

HSMN NewsFeed - 21 May 2008
Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
Biopharmaceuticals

HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals

HSMN NewsFeed - 8 May 2008
New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial
Biopharmaceuticals

HSMN NewsFeed - 1 May 2008
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Apr 2008
FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2008
Cerner and UNMHSC Sign Agreement to Evaluate Dry-Powder Inhaler Drug-Delivery Technology
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 7 Mar 2008
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Diagnostics Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2008
MedImmune Submits Biologics License Application to FDA for Motavizumab
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2008
ALVESCO(R) Gains FDA Approval for the U.S. Market
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Dec 2007
PARI Hydrate Receives FDA Clearance
Devices FDA

HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Dec 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Nov 2007
APT Pharmaceuticals Expands Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2007
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Oct 2007
Study Using PARI Nebulizer Finds COPD Therapy of Nebulizer and Inhaler Combo More Effective than Inhaler Alone
Devices Drug Delivery

HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 4 Oct 2007
Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 3 Oct 2007
Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R)
Biopharmaceuticals HIV/AIDS Drug Delivery

HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2007
bioMerieux Launches VIDAS(R) NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure
Diagnostics Cardiology Regulatory

HSMN NewsFeed - 26 Sep 2007
Spiration, Inc. Announces First Patient Enrollment in U.S. Pivotal Trial of Minimally Invasive Treatment for Severe Emphysema
Devices

HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Sep 2007
Spiration Inc. Announces Positive Results from Pilot Study of Treatment for Patients with Severe Emphysema at European Respiratory Society's Annual Congress
Devices

HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 17 Sep 2007
Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing

HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2007
New Study in Journal of Pediatrics Suggests Synagis(R) (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Transave, Inc. Appoints Mich Soga as Chief Financial Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
Peplin Appoints Chief Commercial Officer
Biopharmaceuticals Dermatology Oncology Personnel

HSMN NewsFeed - 21 May 2007
Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
Biopharmaceuticals

HSMN NewsFeed - 11 May 2007
FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2007
MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
Biopharmaceuticals

HSMN NewsFeed - 1 May 2007
FDA Advisory Committee Finds Substantial Evidence to Support Advair 500/50 in Reducing COPD Exacerbations
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2007
Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals Devices

HSMN NewsFeed - 18 Apr 2007
Imaging Diagnostic Systems' Director of Clinical Research Cautions Against Excess Radiation Dose to Breasts
Devices Radiology Oncology

HSMN NewsFeed - 18 Apr 2007
Pipex Pharmaceuticals Appoints Kay E. Stremler, Ph.D. as Vice President of Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Apr 2007
Aeris Therapeutics Strengthens Management Team
Devices Drug Delivery Personnel

HSMN NewsFeed - 11 Apr 2007
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology

HSMN NewsFeed - 13 Mar 2007
PARI's Hydrate Receives FDA 510k Clearance
Devices FDA

HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jan 2007
Inspire Provides Cystic Fibrosis Clinical Program Update
Biopharmaceuticals

HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2007
Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2007
VIASYS Receives FDA Approval to Market Its PulmoLife(TM) Spirometry Screener
Devices FDA

HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Nov 2006
Numax(R) Achieves Primary Endpoint In Preliminary Analysis of Data From Comparative Phase 3 Trial With Synagis(R)
Biopharmaceuticals

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2006
Bentley Pharmaceuticals Expands Phase II Clinical Trials of Intranasal Insulin Spray to the U.S.
Biopharmaceuticals Drug Delivery Endocrinology

HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 11 Oct 2006
Roche and Trimeris Provide Update on Development of Needle-Free Administration for FUZEON(R)
Biopharmaceuticals Drug Delivery HIV/AIDS

HSMN NewsFeed - 11 Oct 2006
GSK Submits Supplemental Drug Application for Advair in COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Oct 2006
MIMA Cancer Center Treats Lung Cancer With Image-Guided Body Radiosurgery Using Trilogy(TM) Accelerator From Varian Medical Systems
Devices Oncology

HSMN NewsFeed - 5 Oct 2006
Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Oct 2006
New Data Show Unprecedented Undetectable Rates of over 90 Percent in HIV Patients Receiving FUZEON(R) and Investigational Integrase Inhibitor MK-0518
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2006
Quidel Announces FDA 510(k) Clearance of Their New Rapid Test for Detection of Respiratory Syncytial Virus (RSV)
Diagnostics FDA

HSMN NewsFeed - 14 Sep 2006
Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
Biopharmaceuticals Licensing

HSMN NewsFeed - 14 Sep 2006
Exubera Effective in Diabetes Patients who Have Respiratory Infections or are Exposed to Passive Cigarette Smoke, New Analyses Show
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals

HSMN NewsFeed - 20 Jul 2006
GSK Announces U.S. Government Purchase of Relenza(R) for State Stockpiles
Biopharmaceuticals

HSMN NewsFeed - 13 Jul 2006
Hologic Acquires R2 Technology, Inc.
Devices Radiology Oncology Mergers & Acquisitions

HSMN NewsFeed - 26 Jun 2006
New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 May 2006
Actelion: ATS Presentation Highlights Strong Rationale for a Morbidity/Mortality Study with Bosentan in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 8 May 2006
BioE Stem Cell First Human Cord Blood Stem Cell to Turn into Lung Cell
Regenerative Medicine

HSMN NewsFeed - 4 May 2006
Raven Appoints George F. Schreiner, M.D., Ph.D., Chief Executive Officer
Biopharmaceuticals Oncology Personnel

Return to NewsFeed

Additional items found! 169

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 169 additional stories matching:
lung disease
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.